From the ND Dept of Health - FDA Authorization of Intradermal for Adults and Subcutaneous Administration to Children

Tuesday, August 9, 2022

Today, the U.S. Food and Drug Administration (FDA) issued an emergency use authorization (EUA) for the JYNNEOS vaccine to allow healthcare providers to use the vaccine by intradermal injection for individuals 18 years of age and older who are determined to be at high risk for monkeypox infection. This will increase the total number of doses available for use by up to five-fold, as five doses may now be obtained from a single dose vial. The EUA also allows for use of the vaccine in individuals younger than 18 years of age determined to be at high risk of monkeypox infection; in these individuals, JYNNEOS is administered by subcutaneous injection. A copy of the FDA’s press release can be found at Monkeypox Update: FDA Authorizes Emergency Use of JYNNEOS Vaccine to Increase Vaccine Supply | FDA.

Updated CDC clinical considerations regarding these changes are forthcoming. CDC webinars and educational materials regarding this topic are also expected in the near future.

Additional information will be sent to healthcare providers as it becomes available.